{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T13:10:51Z","timestamp":1697980251322},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":9473,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1987,4]]},"abstract":"<jats:p>Pharmacokinetic studies of intermediate and high dose 1\u2010\u03b2\u2010<jats:sc>d<\/jats:sc>\u2010arabinofuranosylcytosine (araC) therapy were performed in 14 children with acute leukemia and four with non\u2010Hodgkin's lymphoma (NHL). AraC administration differed by method, dosage, and time of infusion to obtain the optimal tumorcidal concentration. The toxicity of these regimens was limited to transient severe nausea and vomiting, which were tolerable. Infusion time and dose are important factors to obtain optimal and clinically effective cerebrospinal fluid (CSF) araC concentrations. A concentration of araC above 1 \u03bcg\/mL in CSF, which was lethal to cells in culture, was obtained by intravenous infusion of more than 2,000 mg\/m<jats:sup>2<\/jats:sup> of araC for four hours. We propose that araC 2,000 mg\/m<jats:sup>2<\/jats:sup> by constant intravenous infusion is preferable in the treatment of leukemia and is associated with the fewest side effects.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1987.tb03025.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T23:54:31Z","timestamp":1362786871000},"page":"330-333","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacokinetic Studies of Intermediate\u2010 to High\u2010Dose 1\u2010\u03b2\u2010D\u2010Arabinofuranosylcytosine in Children With Acute Leukemia and Lymphoma"],"prefix":"10.1002","volume":"27","author":[{"given":"Yoshiki","family":"Takashima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197808)42:2 <839::AID-CNCR2820420705>3.0.CO;2-P"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950070105"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1980.tb07340.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1984.tb02898.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840415)53:8<1651::AID-CNCR2820530805>3.0.CO;2-4"},{"key":"e_1_2_1_7_2","first-page":"1587","article-title":"A pilot study of high\u2010dose 1\u2010beta\u2010d\u2010arabinofuranosylcytosine for acute leukemia and refractory lymphoma: Clinical responce and pharmacology","volume":"42","author":"Early AP","year":"1982","journal-title":"Cancer Res"},{"key":"e_1_2_1_8_2","first-page":"3412","article-title":"Pharmacokinetics of N14\u20101\u2010beta\u2010\u0394\u2010arabinofuranosylcytosine in patients with acute leukemia","volume":"43","author":"Ueda T","year":"1983","journal-title":"Cancer Res"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1200\/JCO.1985.3.7.998","article-title":"Sequential high\u2010dose cytosine arabinoside\u2010asparaginase treatment in advanced childhood leukemia","volume":"3","author":"Wells RJ","year":"1985","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)81902-7"},{"key":"e_1_2_1_11_2","first-page":"2737","article-title":"The effects of arabinofuranosylcytosine on cultured human lymphoma cells","volume":"32","author":"Drewink B","year":"1972","journal-title":"Cancer Res"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197910)44:4<1189::AID-CNCR2820440404>3.0.CO;2-O"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820401)49:7<1384::AID-CNCR2820490714>3.0.CO;2-6"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830201)51:3<430::AID-CNCR2820510313>3.0.CO;2-5"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830201)51:3<426::AID-CNCR2820510312>3.0.CO;2-S"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950100705"},{"key":"e_1_2_1_17_2","first-page":"291","article-title":"Plasma half\u2010life of cytosine arabinoside (NSC\u201063878) in patients treated for acute myeloblastic leukemia","volume":"55","author":"Baguley BC","year":"1971","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1971126944"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19821001)50:7<1248::AID-CNCR2820500705>3.0.CO;2-5"},{"key":"e_1_2_1_20_2","first-page":"685","article-title":"Kinetics of effect of 1\u2010beta\u2010d\u2010arabinofuranosylcytosine, its 5\u2010palmitoyl ester, 1\u2010beta\u2010d\u2010arabinofuranosyluracil, and tritiated thymidine on the viability of cultured L1210 cells","volume":"48","author":"Wilkoff IJ","year":"1972","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_1_21_2","first-page":"2627","article-title":"The effect of 1\u2010beta\u2010d\u2010arabinofuranosylcytosine on growth, viability and DNA synthesis of mouse L\u2010cells","volume":"30","author":"Graham FL","year":"1970","journal-title":"Cancer Res"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1987.tb03025.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1987.tb03025.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T10:30:24Z","timestamp":1697884224000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1987.tb03025.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1987,4]]}},"alternative-id":["10.1002\/j.1552-4604.1987.tb03025.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1987.tb03025.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1987,4]]}}}